AstraZeneca widens cancer push with up to $500 mln Heptares deal

LONDON, Aug 6 (Reuters) - AstraZeneca expanded its push into cancer immunotherapy on Thursday by striking a deal potentially worth more than $500 million with Sosei's biotech unit Heptares, giving it rights to an experimental treatment.